Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.